Hepatitis C Clinical Trial
Official title:
Health Education Based on We Media to Promote Patient Adherence to HCV Treatment: A Nationwide Online Randomized Controlled Trial
Verified date | January 2019 |
Source | China Liver Health |
Contact | Mingyang Li |
Phone | 8610-57158696 |
clh[@]liver.org.cn | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
INTRODUCTION: Hepatitis C virus (HCV) is recognized as the leading cause of chronic liver
disease worldwide. However, the screening rate and treatment rate of HCV-infected patients in
China is low, which increases the burden of patients and the infection risk of their family
members. WeChat, an instant messaging software, is used in a very high proportion in China.
Health promotion based on WeChat public platform is a very convenient and effective way of
health education. Therefore, this study plans to apply WeChat to conduct health intervention
for HCV-infected patients. The objective is to explore the effect of We-media-based health
promotion method on the detection rate and treatment rate of HCV-infected and their family
members.
METHOD: Recruitment will be conduct in 10 hospitals in Jilin, Beijing, Henan and Anhui
provinces. The subjects should be patients new diagnosed with hepatitis C at the hospital and
aged 18 to 69. After signing the consent form, eligible participants were selected through
the inclusion and exclusion criteria. 1000 participants will be recruited for the trial.
After completing an baseline reseach by a online questionnaire, patients will be randomly
assigned to receive a targeted short article on HCV weekly or a general health article with
no mention of HCV. The intervention will last three months and a follow-up will be conduct at
three month after the last intervention.
OUTCOMES: The primary outcome is antiviral therapy. The secondary outcomes are cognition and
attitude towards hepatitis C, factors influencing antiviral therapy, time to first treatment
and the compliance of treatment.
Status | Not yet recruiting |
Enrollment | 1000 |
Est. completion date | November 2019 |
Est. primary completion date | November 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 69 Years |
Eligibility |
Inclusion Criteria: - Permanent residents in the province - Ages 18-69 (inclusive) - Both blood anti-HCV test and HCV-RNA test is positive - Familiar with the use of mobile phones and WeChat - Informed consent and voluntary participation in the study Exclusion Criteria: - Temporary staff who come to the city to work, travel or visit relatives, or those who will be living in other cities for a long time - Suffering from other serious diseases - Patients with mental disorder or memory disorder - Pregnant women or those who have a plan to prepare for pregnancy within one year - Refuse to participate in the investigation |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
China Liver Health | Peking University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of antiviral therapy | The rate of antiviral therapy is equal to the number of subjects received antiviral therapy divide by the number of all subjects. | 6 months after the first intervention | |
Secondary | Time to first treatment | This is the interval time between the first intervention and first treatment. We want to know from this outcome how long it takes the subject to receive the health intervention before starting treatment. Thus, we can analyze the relationship between intervention time and treatment behavior. | 6 months after the first intervention | |
Secondary | Cognition and attitude towards hepatitis C | Investigators designed a standardized questionnaire that asked questions about subjects' knowledge and attitudes toward hepatitis C. The scores of the questionnaire were used to evaluate the cognition and attitude of the subjects. | 6 months after the first intervention | |
Secondary | Factors influencing antiviral therapy | The investigators designed a ranking question of factors that interfered with the subjects' treatment in the questionnaire. These factors include: (1) My condition is not serious; (2) I am worried about the side effects of treatment; (3) I am afraid of being discriminated against because someone know I have the disease; (4) I have financial difficulties (or the treatment costs are too high); (5) The process of visiting a doctor is complicated. Subjects can also fill in their own ideas in the blank if they have other factors not mentioned in this questionnaire. Investigators will analyze the extent to which each factor affects a patient's treatment. | 6 months after the first intervention | |
Secondary | The rate of giving up treatment halfway | This rate is used to assess compliance with treatment. This rate is equal to the number of subjects who give up treatment halfway divided by the number of subjects who get treatment. | 6 months after the first intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT03186313 -
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 | |
Completed |
NCT02992184 -
PoC-HCV Genedrive Viral Detection Assay Validation Study
|
N/A |